BIO.DE - Biotest Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303

Full Time Employees2,475

Key Executives

Dr. Bernhard R. M. Ehmer M.D.Chairman of Management and Chief Exec. Officer960kN/A63
Dr. Michael RamrothChief Financial Officer, Head of Fin.s & Central Services and Member of the Board of Management1.01MN/AN/A
Dr. Georg Flo??Chief Operating Officer and Member of the Board of Management678kN/AN/A
Dr. Monika ButtkereitHead of Investor RelationsN/AN/AN/A
Dr. Katrin Bern??sterHead of the Project Management OrganisationN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in clinical immunology, haematology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Cytotect for cytomegalovirus infections; and Fovepta for hepatitis B prophylaxis in newborns. The company??s products also comprise Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; and Pentaglobin to treat bacterial infections. The company??s products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat CMV infections; Fibrinogen to treat fibrinogen deficiency; and IgM concentrate for the treatment of bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

Corporate Governance

Biotest Aktiengesellschaft’s ISS Governance QualityScore as of January 1, 2018 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.